Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared on X:
“4 BCMA + GPRC5D strategies in RRMM:
- Ramantamig: ORR 94%, ≥CR 79%, 24-mo PFS 81%
- Tal + Tec: ORR 80%, ≥CR 52%
- China dual CAR-T: ORR 86%, ≥CR 62%
- BMS-986453: ORR 83% overall; 100% in selected naïve patients
Not head-to-head – but a fascinating race!”
Other articles about myeloma on OncoDaily.